Clinical Research Malaysia (CRM) and intellim Corporation sign MOU to establish strategic partnership


Clinical Research Malaysia (CRM) and Japan’s intellim Corporation have signed a memorandum of understanding (MoU) to establish a new strategic partnership in clinical research.

The MoU outlines the clinical research activities in both Malaysia and Japan, as well as in business development and networking opportunities for both organisations.

"This new partnership will have the potential to expand pharmaceutical and medical device development, especially with regards to new drugs in Malaysia from the Japanese companies.

"With the incoming of these trials, Malaysian patients may benefit from potentially better treatment options and standard of care," it said.

The MoU was signed in Tokyo between CRM’s chief executive officer (CEO), Dr Akhmal Yusof and intellim Corporation’s president and CEO, Masakuni Ukita and witnessed by the Malaysian ambassador to Japan, Datuk Ahmad Izlan Idris.

The cooperation between both parties may result in an inflow of more clinical trials into Malaysia in the next few years since Malaysia has existing experience, facilities, processes, regulations and manpower in conducting clinical trials for over 20 years.

With the current Malaysian Economic Transformation Programme that targets clinical research as one of its main drivers in economic growth, Malaysia has accelerated its efforts to reach out to foreign players in the clinical research field through CRM.

Established by the Health Ministry in 2012, CRM´s role is to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support for quality studies.

intellim Corporation is a contract research organisation (CRO) established in Japan in 2005. It provides clinical development services encompassing regulatory affairs strategic consulting, clinical development of phase I III and post-approval clinical studies, as well as submission for marketing approval support.